Carboplatin 150mg Injection Franchise in Ahmedabad

Chemotherapy Medicine Supplier in Bangalore

Oncology Injection Distributor in Hyderabad

Cancer Treatment Injection Franchise Opportunity in Jaipur

Anti-Cancer Drug Stockist in Mumbai
Carboplatin 150mg Injection Export & Manufacturing in Chandigarh

Home/Products /carboplatin-150mg-injection

Carboplit 150 Injection

Composition : Carboplatin (150mg) Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 15ml

Price : ₹0/-

Please Contact For Best Price

Carboplit 150 Injection contains Carboplatin 150mg, a widely used platinum-based chemotherapy agent for treating various cancers including ovarian, lung, and head & neck malignancies. It interferes with DNA replication in cancer cells, slowing tumor growth and improving patient outcomes when administered under proper oncology protocols.

The injection is formulated for intravenous use, ensuring rapid and controlled delivery of the active drug to target tissues. Its stable formulation and predictable pharmacokinetics make it a preferred choice for oncologists in hospital settings, chemotherapy centers, and specialized cancer treatment units.

For distributors and resellers, Carboplit 150 Injection represents a high-value oncology product, consistently required in hospitals, cancer care centers, and specialized oncology clinics. Its essential role in modern chemotherapy regimens ensures steady demand and recurring usage across urban and metro healthcare markets.

Adding Carboplit 150 Injection to your product range strengthens your oncology and hospital-care segment, opening opportunities in bulk institutional supply, government tenders, private hospital chains, export markets, and third-party manufacturing. Its crucial role in cancer treatment makes it a strategically valuable and profitable product for any medical distributor or wholesaler.

Read More

About the Product

Carboplit 150 Injection contains Carboplatin 150mg, a widely used platinum-based chemotherapy agent for treating various cancers including ovarian, lung, and head & neck malignancies. It interferes with DNA replication in cancer cells, slowing tumor growth and improving patient outcomes when administered under proper oncology protocols.

The injection is formulated for intravenous use, ensuring rapid and controlled delivery of the active drug to target tissues. Its stable formulation and predictable pharmacokinetics make it a preferred choice for oncologists in hospital settings, chemotherapy centers, and specialized cancer treatment units.

For distributors and resellers, Carboplit 150 Injection represents a high-value oncology product, consistently required in hospitals, cancer care centers, and specialized oncology clinics. Its essential role in modern chemotherapy regimens ensures steady demand and recurring usage across urban and metro healthcare markets.

Adding Carboplit 150 Injection to your product range strengthens your oncology and hospital-care segment, opening opportunities in bulk institutional supply, government tenders, private hospital chains, export markets, and third-party manufacturing. Its crucial role in cancer treatment makes it a strategically valuable and profitable product for any medical distributor or wholesaler.

Some patients may experience nausea, vomiting, fatigue, low blood counts, or kidney function changes. Rarely, severe allergic reactions, neurotoxicity, or liver dysfunction may occur.

It is indicated for the treatment of ovarian cancer, lung cancer, head and neck cancers, and other solid tumors as prescribed by an oncologist. It helps reduce tumor size, control disease progression, and improve patient outcomes when administered under supervised therapy.

Use strictly under medical supervision. Monitor blood counts, kidney function, and electrolytes during treatment. Avoid in patients with hypersensitivity to carboplatin or platinum-containing compounds. Administration should only be performed by trained healthcare professionals.

Store in a cool, dry place below 25°C, protected from light. Keep out of reach of children.

Get in Touch